Avita Medical Inc.

Avita Medical is the small-cap regenerative-wound-care company behind the RECELL system — a spray-on skin autograft used for burn wounds and, increasingly, chronic skin defects. The stock has doubled year-over-year and sits near 52-week highs on quiet institutional accumulation, with no X sentiment coverage this window.

• The core growth is real: Q2 revenue of $21.7M grew ~18% year-over-year with an 82% gross margin — the profile of a small-cap medical device company with a defensible technology moat and a growing addressable market.
• The technology thesis is expanding beyond burns: bulls point to Avita's expansion into full-thickness skin defects and diabetic wound care — a category shift that could 10x the addressable market if the FDA-clearance and commercial-adoption cadence lands as management has framed.
• The chart is confirming accumulation: shares sit 68% above the 50-day moving average and 88% above the 200-day, near 52-week highs on modest volume — a low-noise institutional-buying pattern more than a retail-momentum surge.
• The near-term financials are the honest offset: operating margin remains at -32% and consensus FY26 EPS of -$1.05 tells you the company is still burning cash — the path to profitability requires the wound-care volume expansion to actually land in H2.

Coming into Nov 5 earnings, the tape needs Q3 revenue to continue expanding sequentially (above ~$23M) and management to detail the chronic-wound-care commercial ramp. A clean beat plus visible category expansion keeps the trend extending; a slowdown in RECELL adoption or a payer-reimbursement disclosure that pressures the model is what breaks the setup near current highs.